Codexis (CDXS) Set to Announce Earnings on Thursday

Codexis (NASDAQ:CDXS - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, October 31st. Analysts expect Codexis to post earnings of ($0.25) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Codexis (NASDAQ:CDXS - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.06). The firm had revenue of $7.98 million for the quarter, compared to analysts' expectations of $7.64 million. Codexis had a negative return on equity of 64.06% and a negative net margin of 125.41%. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. On average, analysts expect Codexis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Codexis Price Performance

CDXS stock traded down $0.07 during midday trading on Thursday, reaching $2.99. The stock had a trading volume of 431,693 shares, compared to its average volume of 526,214. Codexis has a 52-week low of $1.51 and a 52-week high of $4.91. The company has a current ratio of 2.99, a quick ratio of 2.92 and a debt-to-equity ratio of 0.46. The company's fifty day simple moving average is $3.02 and its 200 day simple moving average is $3.14. The company has a market cap of $210.97 million, a price-to-earnings ratio of -3.22 and a beta of 2.08.

Insider Activity at Codexis

In other news, major shareholder Opaleye Management Inc. acquired 1,055,000 shares of the company's stock in a transaction on Friday, September 20th. The shares were bought at an average price of $3.01 per share, with a total value of $3,175,550.00. Following the completion of the acquisition, the insider now owns 8,390,000 shares in the company, valued at $25,253,900. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders purchased a total of 1,166,000 shares of company stock valued at $3,514,910 over the last ninety days. Insiders own 2.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CDXS. Benchmark lowered shares of Codexis from a "buy" rating to a "hold" rating in a research report on Monday, August 19th. Cantor Fitzgerald reissued an "overweight" rating and set a $11.00 price objective on shares of Codexis in a research note on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Codexis has an average rating of "Hold" and a consensus price target of $8.75.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.